Sector
PharmaceuticalsOpen
₹377Prev. Close
₹380.25Turnover(Lac.)
₹188.29Day's High
₹382.95Day's Low
₹37752 Week's High
₹47552 Week's Low
₹273.6Book Value
₹70.61Face Value
₹5Mkt Cap (₹ Cr.)
1,001.4P/E
44.27EPS
8.61Divi. Yield
1.31Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|
Equity Capital | 13.1 | 13.1 | 13.1 | 13.1 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 145.79 | 119.66 | 108.83 | 97.93 |
Net Worth | 158.89 | 132.76 | 121.93 | 111.03 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 187.94 | 158.56 | 126.53 | 143.87 |
yoy growth (%) | 18.52 | 25.31 | -12.05 | 0.26 |
Raw materials | -80.77 | -56.18 | -61.11 | -58.94 |
As % of sales | 42.97 | 35.43 | 48.29 | 40.97 |
Employee costs | -53.98 | -50.37 | -41.87 | -40.95 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | 21.87 | 9.41 | -11.62 | 1.59 |
Depreciation | -1.08 | -1.12 | -0.31 | -1.99 |
Tax paid | -4.81 | -1.54 | 0.07 | -2.53 |
Working capital | 16.88 | -7.6 | -14.27 | 6.47 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 18.52 | 25.31 | -12.05 | 0.26 |
Op profit growth | 123.59 | -176.82 | -292.53 | -51.15 |
EBIT growth | 125.46 | -190.51 | -358.5 | -54.72 |
Net profit growth | 116.72 | -168.14 | -197.35 | 264.59 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,775.75 | 150.91 | 4,20,027.58 | 237.82 | 0.77 | 4,409.74 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,855.95 | 78.49 | 1,30,370.29 | 430 | 0.61 | 2,063 | 507.93 |
Cipla Ltd CIPLA | 1,574.55 | 32.24 | 1,28,058.81 | 1,055.94 | 0.82 | 3,752.25 | 346.4 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,178.7 | 27.87 | 1,21,729.16 | 1,700.8 | 0.25 | 4,035.4 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,954.5 | 28.24 | 1,16,346.95 | 1,417.2 | 0.57 | 5,823.9 | 1,458.7 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
Manish Gupta
Chairman & Non Executive Dir.
Harsha Raghavan
Independent Director
Debasis Bikash Nandy
Independent Director
Radhika Dudhat
Independent Director
Pallavi Dinodia
Non Executive Director
Prithipal Singh Kochhar
Company Sec. & Compli. Officer
Abhishek Joshi
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Jagsonpal Pharmaceuticals Ltd
Summary
Promoted by J S Kochhar in 1978, Jagsonpal Pharmaceuticals is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana. The company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs. Simultaneously it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd.The company has a strategic alliance with Fidia Spa, Italy; and B Spofola, Czechoslovakia; to manufacture sophisticated drugs in India. It has tied up with another Israel-based company, Makhteshim Chemical Works, for acquiring the marketing rights of an anti-oxidant product. In 1994, the company has also promoted Aresco Financial Services, a new financial company.The Companys R&D activities have resulted in manufacturing process upgradation, improving packaging, and cost containment. Its R&D activities are geared towards development of new product technologies which can be commercialised in future.It has tied up with Lycored Natural Products Industries (LNP) of Israel, to launch a completely natural Lycopene bioactive product, Lycored, in India and SouthEast Asia.In the fiscal 2001, the companys sales grew by 15% to Rs 136.52 crore and the profit at the net level was up 8% to Rs 10.15 crore. This was achieved against heavy odds, such as, sluggish market trends, lower growth rate of the industry and severe competition from dr
Read More
The Jagsonpal Pharmaceuticals Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹378.5 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Jagsonpal Pharmaceuticals Ltd is ₹1001.40 Cr. as of 23 Aug ‘24
The PE and PB ratios of Jagsonpal Pharmaceuticals Ltd is 44.27 and 5.38 as of 23 Aug ‘24
The 52-week high/low is the highest and lowest price at which a Jagsonpal Pharmaceuticals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Jagsonpal Pharmaceuticals Ltd is ₹273.6 and ₹475 as of 23 Aug ‘24
Jagsonpal Pharmaceuticals Ltd's CAGR for 5 Years at 78.22%, 3 Years at 40.41%, 1 Year at -15.61%, 6 Month at 21.91%, 3 Month at 10.60% and 1 Month at 10.84%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.